7S8H image
Entry Detail
PDB ID:
7S8H
Title:
Structure of Lassa virus glycoprotein bound to Fab 18.5C and Fab 36.1F
Biological Source:
Source Organism:
PDB Version:
Deposition Date:
2021-09-17
Release Date:
2022-06-01
Method Details:
Experimental Method:
Resolution:
2.70 Å
R-Value Free:
0.25
R-Value Work:
0.21
Space Group:
P 3 2 1
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Glycoprotein G1
Mutations:G243C, Residues 256-259 mutated from RRLL to RRRR
Chain IDs:A
Chain Length:201
Number of Molecules:1
Biological Source:Lassa virus
Polymer Type:polypeptide(L)
Description:36.1F Fab Heavy Chain
Chain IDs:D (auth: B)
Chain Length:229
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:36.1F Fab Light Chain
Chain IDs:E (auth: C)
Chain Length:216
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:18.5C Fab Heavy Chain
Chain IDs:B (auth: H)
Chain Length:228
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:18.5C Fab Light Chain
Chain IDs:C (auth: L)
Chain Length:217
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:Glycoprotein G2
Mutations:E329P, M332T, I350C
Chain IDs:F (auth: a)
Chain Length:201
Number of Molecules:1
Biological Source:Lassa virus
Ligand Molecules
Primary Citation
Delineating the mechanism of anti-Lassa virus GPC-A neutralizing antibodies.
Cell Rep 39 110841 110841 (2022)
PMID: 35613585 DOI: 10.1016/j.celrep.2022.110841

Abstact

Lassa virus (LASV) is the etiologic agent of Lassa Fever, a hemorrhagic disease that is endemic to West Africa. During LASV infection, LASV glycoprotein (GP) engages with multiple host receptors for cell entry. Neutralizing antibodies against GP are rare and principally target quaternary epitopes displayed only on the metastable, pre-fusion conformation of GP. Currently, the structural features of the neutralizing GPC-A antibody competition group are understudied. Structures of two GPC-A antibodies presented here demonstrate that they bind the side of the pre-fusion GP trimer, bridging the GP1 and GP2 subunits. Complementary biochemical analyses indicate that antibody 25.10C, which is broadly specific, neutralizes by inhibiting binding of the endosomal receptor LAMP1 and also by blocking membrane fusion. The other GPC-A antibody, 36.1F, which is lineage-specific, prevents LAMP1 association only. These data illuminate a site of vulnerability on LASV GP and will guide efforts to elicit broadly reactive therapeutics and vaccines.

Legend

Protein

Chemical

Disease

Primary Citation of related structures